Lidocaína 2% Braun (Lidocaine Hydrochloride)

Lidocaine works by reversibly blocking voltage‑gated sodium channels on nerve membranes. This prevents the influx of sodium ions that is necessary for depolarisation, thereby halting the generation and propagation of action potentials and producing a temporary loss of sensation in the treated area.

The dose of lidocaine is determined by the prescribing clinician based on the type of procedure, the route of administration, patient weight, age, comorbidities and any concurrent medications. Only a qualified health professional should calculate and administer the appropriate amount.

Safety data for lidocaine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Both lidocaine and bupivacaine are amide‑type local anesthetics, but lidocaine has a faster onset and a shorter duration of action, making it suitable for short procedures. Bupivacaine provides a longer block but carries a higher risk of cardiotoxicity at comparable plasma levels, so the choice depends on the clinical need and safety considerations.

Store the solution at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from direct light and moisture, and ensure the vial is tightly sealed to maintain sterility.

Lidocaína 2% Braun is administered by a qualified health professional via injection. The route may be epidural, intramuscular or intravenous, depending on the intended use. Proper aseptic technique and dosage calculation are essential for safe administration.

The most serious risks include systemic toxicity, which can manifest as central nervous system seizures, cardiac arrhythmias, hypotension, and in rare cases, anaphylactic reactions. Early recognition of symptoms such as tinnitus, metallic taste, dizziness, or altered mental status is critical for prompt management.

Lidocaine should be avoided in patients with a known hypersensitivity to amide‑type local anesthetics, those with severe heart block or uncontrolled conduction disorders, and individuals with significant hepatic impairment that could impair metabolism. Caution is also advised in pregnant or lactating women unless the benefit justifies the risk.